Clinical Trials Logo

Clinical Trial Summary

Changes in the metabolic ability of cytochrome P-450 during child development can affect both bioavailability and elimination depending on the involvement of intestinal and hepatic metabolic processes. The age-related variability of cytochrome P-450 isoenzymes in children has been described since 2010. The variability in the development of the activity of specific cytochrome P-450 isoenzymes illustrates why the pharmacogenetic features of the medicine use at different age periods should be studied for individual drugs. This will provide an understanding of the mechanisms for preventing adverse events appearing in pediatric intensive care units while more common antimicrobial pharmacotherapy is administered. Improved knowledge of the pharmacogenetic characteristics of cytochrome P-450 and the unintended consequences of modulation of its isoenzymes could provide an understanding of the susceptibility to adverse events in children in critical conditions staying at Intensive Care unit (ICU).


Clinical Trial Description

An observational prospective multidirectional study on the safety of antimicrobial pharmacotherapy in ICU children aged 0-17. The endpoints of the safety assessment are the frequency of adverse events with antimicrobial agents (AMA); electrocardiography (ECG), fibrinogen concentration, international normalized ratio (INR) and prothrombin index (IPT) at screening and at the end of the treatment course, and pharmacogenetic indicators (a more detailed study of the safety profile). A demonstration of the effectiveness of each of these comparisons of inequality will be based on the hypothesis testing approach, according to which the null hypothesis concludes that there is no difference between groups receiving different AMA combinations for the endpoint of interest; and an alternative hypothesis supposes a difference between treatment groups receiving different AMA combinations. Changes in the sequential organ failure assessment (SOFA) scale in dynamics compared to the baseline will be analyzed using the Mixed-Effect Model Repeated Measure (MMRM) model which assume the baseline, gender, age, AMA combination, and the duration of the AMA course. For a population of subjects aged 0-3 months, the analysis will be performed using the analysis of covariance (ANCOVA) model with the effects of INR, fibrinogen, and IPT values at the initial level for gender, age, and AMA combination in the treatment groups. To assess the secondary endpoint for the general population - the frequency and timing of the transition to de-escalation at ICU, cluster analysis will be conducted to identify the relationship of specific AMA combinations with the possibility of de-escalation in ICU children. Studies will be conducted to reveal the relationship in gene polymorphism encoding isoenzymes of the cytochrome P-450 biotransformation, and the relationship between the activity of transport proteins with the indicators of effectiveness and safety of antimicrobial pharmacotherapy. The lack of pharmacological safety studies in children administered medicine combinations to overcome pan-resistant gram-negative infection provides relevant prerequisites for this study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04141657
Study type Observational
Source National Medical Research Center for Children's Health, Russian Federation
Contact
Status Completed
Phase
Start date February 1, 2020
Completion date October 15, 2021

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT02588560 - Viral Load Changes in Lymphoma Patients With HCV Infection After Chemotherapy N/A
Completed NCT03815487 - Comparison of Two Management Systems in Patients With Type 1 Diabetes (Pediatric SmartHome) N/A
Completed NCT05366621 - Post-fracture Medication and Mortality
Recruiting NCT03487939 - Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer Phase 2
Recruiting NCT04478838 - "Extended" (Alternate Day) Antipsychotic Dosing Phase 4
Recruiting NCT05322967 - Effect of Chronotherapy on Blood Pressure - Time of Intake of Blood Pressure Lowering Drugs N/A
Not yet recruiting NCT01131429 - A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations Phase 2
Recruiting NCT06223568 - Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer Phase 2
Completed NCT04627077 - Livestrong Cancer Institutes' Patient Reported Outcomes Study
Recruiting NCT06009965 - Efficacy of IST Combined With TPO-RA in the Treatment of AA and Establishment of a Recurrence Prediction System Phase 4
Completed NCT03551457 - Potential Therapeutic Response In Urogenital Tumors
Completed NCT04095104 - Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds Phase 2
Recruiting NCT04996732 - Long-term Survivorship of Discharged Patients With Malignant Tumor Based on Single-institutional Cancer Registry
Not yet recruiting NCT05246722 - Registry Study of Pharmacotherapy and Clinical Outcomes in Elderly Patients With Coronary Heart Disease (PHARM-ageing)
Not yet recruiting NCT04184583 - Registry Study on Drug Therapy and Clinical Outcomes in Patients With Acute Coronary Syndrome
Completed NCT04493905 - Effects of Anesthetic Techniques on Time to Start of Adjuvant Chemotherapy Following Surgery for Colorectal Cancer
Completed NCT01199393 - Genetic Polymorphisms Predict Chemotherapeutic Outcomes in Patients With Metastatic Breast Cancer N/A
Recruiting NCT03484221 - Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer Phase 2
Recruiting NCT03484195 - Neoadjuvant FOLFOXIRI Chemotherapy in Patients With Locally Advanced Colon Cancer Phase 2
Completed NCT00122122 - Randomized Controlled Trial of Enhanced Pharmacy Care in Older Veteran Outpatients Phase 3